Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 2/20 | 0.49 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.49 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.49 |
| ▸ | TOP2A | P11388 | 6/20 | 0.42 |
| ▸ | TOP2B | Q02880 | 6/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.40 |
| ▸ | F3 | P13726 | 3/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cabenoside D SCHEMBL30340049 | 1.00 | PRKAG1 (0.49) | PRKAG1PRKAA2PRKAB1TOP2ATOP2B | |
| SCHEMBL18805317 | 0.94 | PRKAG1 (0.42) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| SCHEMBL18823922 | 0.93 | PRKAG1 (0.48) | PRKAG1PRKAA2PRKAB1TOP2ATOP2B | |
| SCHEMBL29636989 | 0.93 | PRKAG1 (0.41) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| SCHEMBL18815980 | 0.93 | PRKAG1 (0.41) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| SCHEMBL23685845 | 0.91 | TYR (0.43) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| SCHEMBL18818006 | 0.91 | TYR (0.43) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| SCHEMBL18805297 | 0.91 | PRKAG1 (0.40) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| SCHEMBL29521629 | 0.91 | PRKAG1 (0.40) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| SCHEMBL24503392 | 0.91 | PRKAG1 (0.40) | PRKAG1PRKAA2PRKAB1F3PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| EP-3368542-B1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210227863-A1 | HIGH INTENSITY SWEETENERS | SENOMYX, INC. | 2021-07-29 | — | — | US | disclosed |
| US-20170119032-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED | 2017-05-04 | — | — | US | disclosed |
| US-20170119032-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119032-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | PRKAG1 1642/4885PRKAA2 1849/4885PRKAB1 1634/4885 |
| US-11357246-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | PRKAG1 1642/4885PRKAA2 1849/4885PRKAB1 1634/4885 |
| US-20210227863-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | PRKAG1 1642/4885PRKAA2 1849/4885PRKAB1 1634/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | PRKAG1 1642/4885PRKAA2 1849/4885PRKAB1 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.